Company

Replimune Group, Inc.

Woburn, US biotechnology company developing oncolytic immunotherapies for solid tumor cancers, including RP1 and RP2.

About

Founded in 2015 and headquartered in Woburn, US, Replimune Group, Inc. is a biotechnology company developing oncolytic immunotherapies for cancer. Its candidates RP1 and RP2 are in clinical trials for solid tumors including melanoma, liver cancer and non-melanoma skin cancers. The company raised USD 225.00 mn in a Private Placement/Follow on in December 2022, and CEO Philip Astley-Sparke leads it. It is at the Series B stage.

3Funding rounds

7Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in